Author's response to reviews

Title: COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling and stimulates breast cancer cell migration

Authors:

Antoine Boudot (ABoudot@tuftsmedicalcenter.org)
Gwenneg Kerdivel (gwkerdiv@gmail.com)
Sylvain Lecomte (sylvain.lecomte@univ-rennes1.fr)
Gilles Flouriot (gilles.flouriot@univ-rennes1.fr)
Mireille Desille (mireille.desille@univ-rennes1.fr)
Florence Godey (f.godey@rennes.unicancer.fr)
Jean Leveque (jean.leveque@chu-rennes.fr)
Patrick Tas (ptas@atalante-pathologie.fr)
Yves Le Drean (yves.le-drean@univ-rennes1.fr)
Farzad Pakdel (farzad.pakdel@univ-rennes1.fr)

Version: 9  Date: 28 May 2014

Author's response to reviews: see over
From: Dr. Farzad Pakdel

To: BMC Cancer Editorial Office

MS: 6738404851187682

Dear Editor,

Please find our manuscript (MS: 6738404851187682-rev4) entitled “COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling and stimulates breast cancer cell migration”, that has been accepted for publication in BMC Cancer. As requested, we have now clarified that we have received written informed consent from all patients for the use of their samples analyzed in this study. We have also stated that the research protocol was conducted under French legal guidelines and approved by the ethics committee. We have included all these details in the methods section, page 9, 1st paragraph, of the manuscript.

Thank you very much for considering and handling our manuscript.

Yours sincerely,

F. PAKDEL (Ph D)
Phone: (33) 2 23 23 51 32
Fax: (33) 2 23 23 67 94
E-mail: Farzad.Pakdel@univ-rennes1.fr